Organoid Sciences Q1 2026: Revenue Declines, Operating Loss Continues, ATORM-C Crohn's Disease Phase 1 IND Approved

Consolidated revenue: KRW 143.6M (YoY -43.6%), separate revenue: KRW 153.8M (YoY -43.9%)
Consolidated net loss: KRW 4.41B (EPS -670), separate net loss: KRW 3.56B (EPS -541)
R&D expenses: KRW 1.56B, 1,017% of revenue, showing heavy investment
ATORM-C phase 1 IND for Crohn's disease approved on March 13, 2026
Advanced regenerative medicine clinical study for Behcet's enteritis: 5 patients enrolled, 4 treated
IP portfolio: 36 registered patents, 71 patent applications
Cash and equivalents: consolidated KRW 3.42B, separate KRW 1.68B; total financial assets KRW 19.4B
Total borrowings: KRW 5.45B (short-term KRW 3B, long-term KRW 2.45B); collateral provided KRW 2.4B
Six subsidiaries (Vietnam, Germany, Singapore, USA, Japan, PodoTherapeutics)
Global organoid market expected to grow at 21.9% CAGR; designated as national advanced strategic technology